Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.

Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1473-1477. doi: 10.1016/j.bbmt.2017.05.020. Epub 2017 May 22.

2.

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.

Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1445-51. doi: 10.1016/j.bbmt.2015.04.001. Epub 2015 Apr 6.

3.

Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review.

Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B.

Biol Blood Marrow Transplant. 2009 Aug;15(8):893-902. doi: 10.1016/j.bbmt.2009.01.022. Epub 2009 Apr 2. Review.

4.

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.

Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN.

Amyloid. 2016 Dec;23(4):254-259. Epub 2016 Nov 23.

5.

Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.

Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, Majhail NS, Liu HD.

Bone Marrow Transplant. 2016 May;51(5):732-4. doi: 10.1038/bmt.2015.326. Epub 2016 Jan 4. No abstract available.

PMID:
26726941
6.

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kumar SK, Kapoor P, Kourelis TV, Hogan WJ, Gertz MA.

Blood Adv. 2018 Apr 10;2(7):769-776. doi: 10.1182/bloodadvances.2018016782.

7.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK.

J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.

PMID:
30615550
8.

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.

Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P.

Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):165-172. doi: 10.1016/j.clml.2016.11.006. Epub 2016 Nov 25.

PMID:
28159578
9.

At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.

Shen KN, Feng J, Huang XF, Zhang CL, Zhang CL, Cao XX, Zhang L, Zhou DB, Li J.

Ann Hematol. 2017 Dec;96(12):2089-2094. doi: 10.1007/s00277-017-3132-5. Epub 2017 Sep 27.

PMID:
28956112
10.

Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.

Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN.

Bone Marrow Transplant. 2015 Jul;50(7):914-7. doi: 10.1038/bmt.2015.73. Epub 2015 Apr 27.

PMID:
25915809
11.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R.

Ann Oncol. 2018 Mar 1;29(3):724-730. doi: 10.1093/annonc/mdx791.

12.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.

Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. doi: 10.1016/j.bbmt.2016.11.011. Epub 2016 Nov 15.

13.

Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.

Chen W, Ren G, Zuo K, Huang X.

Medicine (Baltimore). 2018 Dec;97(50):e13589. doi: 10.1097/MD.0000000000013589.

14.

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.

Dittus C, Uwumugambi N, Sun F, Sloan JM, Sanchorawala V.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1729-1732. doi: 10.1016/j.bbmt.2016.05.027. Epub 2016 Jun 11.

16.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.

Rosengren S, Mellqvist UH, Nahi H, Forsberg K, Lenhoff S, Strömberg O, Ahlberg L, Linder O, Carlson K.

Bone Marrow Transplant. 2016 Dec;51(12):1569-1572. doi: 10.1038/bmt.2016.249. Epub 2016 Oct 3.

PMID:
27694943
17.

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P.

J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14.

18.

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.

Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN.

Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. doi: 10.1016/j.bbmt.2013.12.557. Epub 2013 Dec 14.

19.

Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience.

Azorín SE, Cibeira MT, Solé M, Fernández de Larrea C, Rosiñol L, Rovira M, Campistol JM, Bladé J.

Amyloid. 2017 Mar;24(sup1):70-71. doi: 10.1080/13506129.2017.1293646. No abstract available.

PMID:
28434321
20.

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):424-430.e1. doi: 10.1016/j.clml.2014.02.003. Epub 2014 Feb 16.

PMID:
24650974

Supplemental Content

Support Center